Skip to main content
. 2020 Apr 3;13(4):100767. doi: 10.1016/j.tranon.2020.100767

Figure 3.

Figure 3

Loss of either S6K1 or S6K2 does not impair the angiogenic capacity of endothelial cells in vitro. (A and B) Cell proliferation assessed by cell count (A) and BrdU incorporation assay (B) in primary S6k1−/−, S6k2−/−, and wild-type endothelial cells grown in complete growth medium. (C and D) Cell proliferation measured by cell count (C) and BrdU incorporation assay (D) in primary S6k1−/−, S6k2−/−, and wild-type endothelial cells treated with 50 ng/ml VEGF for 72 and 48 hours, respectively. (E) Representative bright-field images of endothelial tube formation in S6k1−/−, S6k2−/−, and wild-type endothelial cells (left panel) and quantification of total tube length (right panel). (F) Apoptotic cell death assessed by staining for Annexin-V and flow cytometry analysis in S6k1−/−, S6k2−/−, and wild-type endothelial cells incubated in 50 ng/ml VEGF in starvation medium, starvation medium only, or complete growth medium as controls for 72 hours. Scale bars: 50 μm. Data are presented as means ± SEM.